Drug intelligence / Profile preview

VGV-X

Development stage: Unknown
Lead developer: VG Life Sciences
Administration: Intramuscular

Overview

VGV-X is an experimental HIV/AIDS therapeutic candidate developed by Viral Genetics (later VG Life Sciences) as part of its metabolic and immunomodulatory approach to treating patients who have failed conventional antiretroviral therapy. Public disclosures describe VGV-X as a follow‑on or optimized agent intended to address limitations observed with the company’s earlier HIV drug, with the goal of modulating host immune and metabolic pathways that influence HIV replication and persistence rather than directly inhibiting viral enzymes. Detailed molecular structure, target, and clinical development data have not been publicly characterized, and there is no evidence of active clinical trials or regulatory filings for this compound.

Other names: VGV-X

Beyond the preview

Go deeper on VGV-X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VGV-X.

Explore the full profile